Source-grounded facts extracted from Prestige Consumer Healthcare Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Prestige Consumer Healthcare Inc. entered into Asset Purchase Agreement with Foundation Consumer Brands, LLC valued at $1.045 billion in cash (effective 2026-03-19).
“On March 19, 2026, Prestige Brands, Inc. (“Purchaser”), a Delaware corporation and a wholly-owned subsidiary of Prestige Consumer Healthcare Inc. (the “Company”), entered into a definitive agreement (the “Asset Purchase Agreement”) with Foundation Consumer Brands, LLC (“Foundation”), a Delaware limited liability company. The Asset Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, Purchaser will acquire certain assets and assume certain liabilities primarily related to a portfolio of over-the-counter consumer health products, including Breathe Right® and certain other brands, for $1.045 billion in cash”
Christine Sacco was appointed as Chief Operating Officer at Prestige Consumer Healthcare Inc..
“On January 6, 2025, Prestige Consumer Healthcare Inc. (the “Company”) announced that the Company’s Chief Financial Officer, Christine Sacco, age 49, has also been appointed Chief Operating Officer, effective January 6, 2025.”
Earnings Releases
Prestige Consumer Healthcare Inc. reported the fiscal year ended March 31, 2024 results: revenue $1,125.4 million, net income $209.3 million, EPS $4.17. Guidance initiated.
“Reported revenues for the fiscal year 2024 totaled $1,125.4 million compared to revenues of $1,127.7 million for the fiscal year 2023. Revenues increased 0.2% excluding the impact of foreign currency. Revenue performance for the fiscal year was driven by strong International OTC segment performance and strong Eye & Ear Care, GI, and Dermatological category sales in North America, partially offset by lower Women’s Health, Cough & Cold, and Analgesic category sales and the strategic exit of private label revenues. Reported net income for fiscal 2024 of $209.3 million compared to the prior year comparable period net loss of $82.3 million. Reported Fiscal 2024 diluted earnings per share was $4.17, compared to diluted loss per share of $1.65 in the prior year comparable period.”
Earnings Releases
Prestige Consumer Healthcare Inc. reported the fiscal quarter ended March 31, 2024 results: revenue $277.0 million, net income $49.5 million, EPS $0.98. Guidance initiated.
“Reported revenues in the fourth quarter of fiscal 2024 of $277.0 million compared to $285.9 million in the fourth quarter of fiscal 2023. Revenues decreased 2.9% excluding the impact of foreign currency. The revenue decline in the quarter was attributable to the inability to supply customer orders late in the quarter in certain brands, the strategic exit of private label revenues, and a lower Women’s Health category, partially offset by growth in the International OTC segment. Reported net income for the fourth quarter of fiscal 2024 was $49.5 million versus the prior year comparable quarter’s net loss of $240.6 million. Diluted earnings per share of $0.98 for the fourth quarter of fiscal 2024 compared to a $4.83 diluted loss per share in the prior year comparable period.”
John F. Kelly was elected as Director at Prestige Consumer Healthcare Inc..
“The Company today announced that John F. Kelly, former Vice President Quality Operations and Environment, Health & Safety at Pfizer Inc. was elected to the Company’s Board of Directors on May 7, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.